BRAF and neoplasm: Meanwhile, BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) gene mutation, principally the V600E variant, is detected in 8–15% of CRC patients and is correlated with more aggressive tumor progression and poorer survival outcomes [6, 8].